Stereotactic Ablative Radiotherapy for Pulmonary Oligometastases and Oligometastatic Lung Cancer
Journal of Thoracic Oncology, ISSN: 1556-0864, Vol: 9, Issue: 10, Page: 1426-1433
2014
- 52Citations
- 78Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations52
- Citation Indexes52
- 52
- CrossRef41
- Captures78
- Readers78
- 78
Review Description
An increasing body of experience suggests that oligometastasis represents a minimal metastatic state with the potential for cure or prolonged survival in selected patients treated with radical local therapy to all identified sites of disease. The main clinical scenarios managed by thoracic oncology specialists are pulmonary oligometastases from primary malignancies of other anatomic sites and primary lung cancer with oligometastases to lung or other organs. Surgery has been a mainstay of treatment in these situations, with remarkably favorable outcomes following pulmonary metastasectomy in well-selected patient cohorts. As with early stage lung cancer in patients who are medically inoperable, stereotactic ablative radiotherapy is emerging as a prominent local treatment option for oligometastatic disease. We review the role and clinical experience of stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1556086415306973; http://dx.doi.org/10.1097/jto.0000000000000317; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84925823911&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/25170641; http://linkinghub.elsevier.com/retrieve/pii/S1556086415306973; http://api.elsevier.com/content/article/PII:S1556086415306973?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1556086415306973?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S1556086415306973; http://dx.doi.org/10.1097/JTO.0000000000000317; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01243894-201410000-00003; http://pt.wkhealth.com/pt/re/lwwgateway/landingpage.htm;jsessionid=WBbpfy1jyjLBkytyLG76xJq0yryLWM9vQSQsv91qMwGTNc1yGL8y!582453211!181195628!8091!-1?sid=WKPTLP:landingpage&an=01243894-201410000-00003
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know